Panacea Pharmaceuticals, Inc. Appoints Christopher Kircher, M.D. as Chair of Medical Advisory Board.Business Editors & Health/Medical Writers BIOWIRE2K ROCKVILLE, Md.--(BW HealthWire)--July 7, 2000 Panacea Pharmaceuticals, Inc. is pleased to announce that it has appointed Christopher Kircher, M.D. as Chairman of its Medical Advisory Board. Dr. Kircher is currently a Neurologist and Site Coordinator of Research in Ohio for Riverhills Healthcare, Inc. of Cincinnati, Ohio “Cincinnati” redirects here. For other uses, see Cincinnati (disambiguation). Cincinnati is a city in the U.S. state of Ohio and the county seat of Hamilton County. . He has received a National Institute of Health Research Fellowship and an International Brain Research Organization UNESCO UNESCO: see United Nations Educational, Scientific, and Cultural Organization. UNESCO in full United Nations Educational, Scientific and Cultural Organization Fellowship. Dr. Kircher is currently the principal investigator for on-going clinical trials in multiple sclerosis, migraine, and others. He is the originator and principal investigator for the Community Hypertension Screening Program at the Linder Center for Cardiovascular Research as well as an investigator and neurologist for the carotid artery carotid artery n. 1. An artery that originates on the right from the brachiocephalic artery and on the left from the aortic arch, runs upward into the neck and divides opposite the upper border of the thyroid cartilage, with the external and angioplasty and stenting study at the Christ Hospital in Cincinnati. Dr. Kircher is a frequent invited speaker and lecturer for companies such as Glaxo-Wellcome, Novartis, Biogen, and Merck on subjects ranging from Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. to hypertension to Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. . Dr. Kircher has served or currently serves as a consultant or advisor to Novartis, Merck, and Glaxo-Wellcome. He is a medical advisory board member for Auburn Medical Imaging. Dr. Kircher was formerly Chair of the Medical Advisory Board for Nymox Corporation and currently holds this position for Alzheimer's Corporation. Dr. Kircher received his medical degree from Indiana University School of Medicine The Indiana University School of Medicine is the medical school of Indiana University, part of the Indiana University Purdue University at Indianapolis (IUPUI) campus located in Indianapolis, Indiana. Established in 1903, the school had an initial class of 25 students. and completed his internship at St. Joseph Infirmary in Louisville, a junior neurology residency at the University of Minnesota (body, education) University of Minnesota - The home of Gopher. http://umn.edu/. Address: Minneapolis, Minnesota, USA. Affiliated Hospitals, and senior and chief residencies in neurology at the University of Cincinnati The University of Cincinnati is a coeducational public research university in Cincinnati, Ohio. Ranked as one of America’s top 25 public research universities and in the top 50 of all American research universities,[2] Medical Center. Dr. Kircher is board certified board certified, adj the status of a dental specialist such as an orthodontist who has become a board diplomate by successfully completing the certification program of the recognized certification board in that area of practice. and licensed in both Ohio and Kentucky. "The addition of Dr. Kircher is an honor and a pleasure for us at Panacea," said Hossein A. Ghanbari, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Panacea. "With Chris' leadership and guidance, we will be able to quickly expand our Medical Advisory Board's membership and move towards a representative and formidable team that will effectively interface with neurologists and other specialists." Dr. Kircher stated, "It's a real thrill to be working with Panacea's excellent team in support of its cutting-edge and compelling technology. I'm particularly excited at being involved in and contributing to Panacea's Alzheimer's disease projects, which have been developed by some of the field's top minds and have been finely integrated to provide real promise towards the treatment of this horrible disease." About Panacea Pharmaceuticals Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system such as Alzheimer's disease, brain tumors, transmissible spongiform encephalopathies, and Lewy body diseases such as Parkinson's disease. Changes in disease-relevant proteins by altered expression, post-translational modification, and functional variation are utilized to develop diagnostic tests and therapeutic agents. More information is available at www.PanaceaPharma.com, a web site developed by Ei Web Promotion, a division of eiCommunications.com, Inc. (www.eiCommunications.com), which offers integrated communications and web development solutions for the Information Age. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion